GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes Mellitus

Completed

• Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
• Interventions: Behavioral: No treatment given; Behavioral: survey

• Registration Number: NCT01950650
• Lead Sponsor: Novo Nordisk A/S

Brief Summary

This study is conducted in Asia, Europe and in the United States of America. The aim of this study is to examine patient and physician beliefs regarding insulin therapy and the degree to which patients adhere to their insulin regimens.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-03
• Primary Completion: 2010-09
• Study Completion: 2010-09
• Study First Submitted: 2013-09-23
• Study First Submitted QC: 2013-09-23
• Study First Posted: 2013-09-25
• Status Verified: 2017-04
• Last Update Submitted: 2017-04-25
• Last Update Posted: 2017-04-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1800

Inclusion Criteria

• PATIENTS WITH DIABETES:
• Age 18 years or older
• Treated with insulin
• Type 1 or Type 2 diabetes
• PHYSICIANS:
• In practice for more than 1 year since completing residency
• See a minimum number of patients with diabetes per week (primary care physicians 5, specialists 10)
• Initiate insulin treatment for patients with diabetes

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients with diabetes	No treatment given	-
Physicians	survey	-

Primary Outcome Measures

Name	Time	Method
Frequency of insulin omission/non-adherence	In the past 30 days prior to the day when responding to the survey (patient survey)
Reasons for insulin omission/non-adherence reported by patient and physician	Day 1 (when responding to the survey)

Secondary Outcome Measures

Name	Time	Method
Impact of insulin treatment on life domains (patient survey)	Day 1 (when responding to the online questionnaire)

Trial Locations

Locations (1)

Novo Nordisk Investigational Site; 🇬🇧 Crawley, United Kingdom